HC Wainwright & Co. Maintains Buy on Aprea Therapeutics, Lowers Price Target to $1.2

HC Wainwright & Co. analyst Joseph Pantginis maintains Aprea Therapeutics (NASDAQ:APRE) with a Buy and lowers the price target from $4 to $1.2.